- Home
- ITOS vs DSM Comparison
ITOS vs DSM Comparison
Compare ITOS & DSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITOS
- DSM
- Stock Information
- Founded
- ITOS 2011
- DSM 1989
- Country
- ITOS United States
- DSM United States
- Employees
- ITOS N/A
- DSM N/A
- Industry
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- DSM Investment Managers
- Sector
- ITOS Health Care
- DSM Finance
- Exchange
- ITOS Nasdaq
- DSM Nasdaq
- Market Cap
- ITOS 323.2M
- DSM 304.0M
- IPO Year
- ITOS 2020
- DSM N/A
- Fundamental
- Price
- ITOS $9.17
- DSM $6.00
- Analyst Decision
- ITOS Strong Buy
- DSM
- Analyst Count
- ITOS 4
- DSM 0
- Target Price
- ITOS $32.50
- DSM N/A
- AVG Volume (30 Days)
- ITOS 692.7K
- DSM 161.7K
- Earning Date
- ITOS 11-15-2024
- DSM 01-01-0001
- Dividend Yield
- ITOS N/A
- DSM 3.97%
- EPS Growth
- ITOS N/A
- DSM N/A
- EPS
- ITOS N/A
- DSM N/A
- Revenue
- ITOS $35,000,000.00
- DSM N/A
- Revenue This Year
- ITOS $271.18
- DSM N/A
- Revenue Next Year
- ITOS N/A
- DSM N/A
- P/E Ratio
- ITOS N/A
- DSM N/A
- Revenue Growth
- ITOS N/A
- DSM N/A
- 52 Week Low
- ITOS $8.41
- DSM $4.69
- 52 Week High
- ITOS $18.75
- DSM $6.05
- Technical
- Relative Strength Index (RSI)
- ITOS 46.37
- DSM 41.14
- Support Level
- ITOS $8.41
- DSM $5.92
- Resistance Level
- ITOS $9.14
- DSM $6.13
- Average True Range (ATR)
- ITOS 0.49
- DSM 0.07
- MACD
- ITOS 0.21
- DSM -0.01
- Stochastic Oscillator
- ITOS 71.58
- DSM 23.64
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.